H.C. Wainwright reiterated its Buy rating and $80.00 price target for Corcept Therapeutics (NASDAQ:CORT), highlighting the company's consistent growth in Korlym sales over the past eight quarters ...

H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza ...

H.C. Wainwright initiated coverage of Vertical Aerospace (EVTL) with a Buy rating and $12 price target The company specializes in designing ...

Equities researchers at StockNews.com initiated coverage on shares of SenesTech (NASDAQ:SNES – Get Free Report) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock ...

Fintel reports that on February 6, 2025, HC Wainwright & Co. initiated coverage of Harrow (NasdaqGM:HROW) with a Buy ...

We recently compiled a list of the 10 Trending AI Stocks That Analysts Are Monitoring. In this article, we are going to take ...

On Tuesday, H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a price target of $180.00. According to InvestingPro data, this ...

HC Wainwright analyst M. Kapoor now anticipates that the biotechnology company will post earnings of $2.45 per share for the quarter, up from their previous forecast of $2.35.

On Thursday, H.C. Wainwright reaffirmed its Buy rating and $20.00 stock price target for Aprea Therapeutics (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel ...

Rufus Wainwright’s latest classical opus, Dream Requiem, is both beautiful and grimly apposite. Originally composed during lockdown in his Laurel Canyon home while wildfires raged around him ...